Choose Your Location
|
![]() |
BRISBANE, Calif. (Map) -
"We believe a multi-drug strategy is the best approach to battling GBM.
There is a significant need for new treatments that can offer GBM patients and
their families additional hope," said
"BSI-201 is a promising agent that has been well tolerated in combination with cytotoxic therapies in patients with solid tumors and potentially addresses a key pathway by which GBM cells resist the effects of existing medications. We are hopeful that BSI-201 will safely potentiate the power of current therapies for GBM and improve survival in this difficult-to-treat cancer," said
"The scientific observations that BSI-201 crosses the blood-brain barrier
and has a mechanistic basis to synergize with the standard treatment of GBM
makes this a promising study," said BiPar Executive Vice President
GBM is an aggressive form of brain cancer that strikes 10,000 patients a
year in
Additional Data to be Presented at Upcoming AACR 2008 Meeting
BiPar will present preclinical data on BSI-201 at the American Association
for Cancer Research (AACR) Annual Meeting in
About BiPar Sciences
BiPar Sciences is a drug development company with a therapeutic focus on novel mechanisms of action in oncology. Our existing platform is based on DNA repair, specifically with poly ADP-ribose polymerase (PARP) inhibitors. BSI-201 is the lead PARP inhibitor program in Phase 2 clinical trials in multiple solid tumor settings.
|
|


